

2016 Pharmacogenetics in Psychiatry Meeting Schedule

Session One: Biomarkers of Antipsychotic Drug Response

- 8:30AM-8:55AM: Eric Huang, BSc, Centre for Addiction & Mental Health, Toronto Canada
"Preliminary Model for Genetic Prediction of Clozapine Response"
- 8:55AM-9:20AM: Miklos Argyelan, MD, Hofstra Northwell School of Medicine, Hempstead NY
"Neural Circuitry of Acute Antipsychotic Response"
- 9:20AM-9:45AM: Vicki Ellingrod, PharmD, FCCP, University of Michigan, Ann Arbor MI
"Impact of OPRM1 on Metabolic Consequences of Atypical Use"
- 9:45AM-10:10AM: Yuka Kikuchi, MD, Akita University Graduate School of Medicine, Akita City Japan
"The Effectiveness of Clozapine in Reducing Medical Costs Associated with Treatment-Resistant Schizophrenia in Japanese Patients"
- 10:10AM-10:20AM: BREAK

Session Two: Novel Approaches to Drug Discovery

- 10:20AM-10:45AM: Faith Gunning, PhD, Weill Cornell Medical College, New York NY
"The Use of Cognitive Neuroscience Techniques for Development of Novel Treatments for Late-Life Depression"
- 10:45AM-11:10AM: Aristotle Voineskos, MD, PhD, Centre for Addiction & Mental Health, Toronto Canada
"Genetic Epistasis Regulates Amyloid Deposition in Resilient Aging"
- 11:10AM-11:35AM: Cathy Barr, PhD, Krembil Research Institute and the Hospital for Sick Children, Toronto Canada
"Enhancers and Super-enhancers in Psychiatric Disease: Genome-wide Interaction Predictions and Functional Studies Using CRISPR/Cas9 Genome-editing"
- 11:35AM-12:00PM: Kristen Brennand, PhD, Mount Sinai School of Medicine, New York NY
"iPSc in New Drug Development"
- 12:00PM-1:30PM: LUNCH

Session Three: Biomarkers of Response to Antidepressants and Mood Stabilizers

- 1:30PM-1:55PM: Daphne Voineskos, MD, FRCPC, Centre for Addiction & Mental Health, Toronto Canada
"A Comparison of Cortical Inhibition in a Sample of Treatment Resistant Depression Patients Pre and Post rTMS Treatment"
- 1:55PM-2:20PM: Katherine Burdick, PhD, Mount Sinai School of Medicine, New York NY
"A Systematic Approach to Determining the Effects of Lithium on Neurocognitive Performance In Patients with Bipolar Disorder"
- 2:20PM-2:45PM: Gwyneth Zai, PhD, Centre for Addiction & Mental Health, Toronto Canada
"Pharmacogenetics of Antidepressant Response in Obsessive-Compulsive Disorder: DISP1 Genetic Variant"

2016 Pharmacogenetics in Psychiatry Meeting Schedule

2:45PM-3:10PM: John Kelsoe, MD, University of California-San Diego, La Jolla CA
"Identifying SNPs Associated with Good Lithium Response Using a Combined Analysis of Stem Cell Derived Neurons and Genome-wide Association"

3:10PM-3:30PM: BREAK

Session Four: Applications of Pharmacogenetics

3:30PM-3:55PM: Andrius Baskys, MD, Riverside Psychiatric Medical Group, Riverside CA
"Decrease in Psychotropic Prescription Changes Made By Community Psychiatrists After Pharmacogenetic Testing"

3:55PM-4:20PM: Beatriz Carvalho Henriques, PhD, University of Alberta, Edmonton Canada
"CYP2D6: Detecting New Structures for Clinical Practice"

4:20PM-4:45PM: James Kennedy, MD, Centre for Addiction & Mental Health, Toronto Canada
"Drug Discovery and Development Using Pharmacogenetics"